Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. The JAMA Report™

Reducing the High Cost of Prescription Drugs in the U.S.

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Related
Comments
  • In Partnership with

  • Overview

    [Read the Article]

    The increasing cost of prescription drugs in the United States has become a source of growing concern for patients, prescribers, payers, and policy makers.  A new study examined the reasons for these high prices and also suggests policy changes that could help contain costs.
     
    Researchers from Brigham and Women’s Hospital reviewed the medical and health policy literature on prescription drug prices in the U.S. and found high drug costs stem from various factors such as market exclusivity, limitations on payers and their ability to negotiate prices, and limitations on competition.
     
    The researchers state that the most realistic short-term strategies include enforcing stricter requirements for exclusivity rights, ensuring timely generic drug availability, providing greater opportunities for price negotiation by patients, and effectively educating patients, prescribers, payers, and policy makers about these choices.

    [Watch more videos of The JAMA Report]

Recommended
Details
Related
Comments
  • In Partnership with

  • Overview

    [Read the Article]

    The increasing cost of prescription drugs in the United States has become a source of growing concern for patients, prescribers, payers, and policy makers.  A new study examined the reasons for these high prices and also suggests policy changes that could help contain costs.
     
    Researchers from Brigham and Women’s Hospital reviewed the medical and health policy literature on prescription drug prices in the U.S. and found high drug costs stem from various factors such as market exclusivity, limitations on payers and their ability to negotiate prices, and limitations on competition.
     
    The researchers state that the most realistic short-term strategies include enforcing stricter requirements for exclusivity rights, ensuring timely generic drug availability, providing greater opportunities for price negotiation by patients, and effectively educating patients, prescribers, payers, and policy makers about these choices.

    [Watch more videos of The JAMA Report]

Schedule22 Nov 2024